J&J Gets CDSCO Panel Nod to study anti-cancer drug Talquetamab
New Delhi: The drug major Johnson and Johnson has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III clinical study of the anti-cancer drug Talquetamab. This came after the firm presented Phase III Clinical Study Protocol No. 64407564MMY3009. Talquetamab is a bispecific […]